GlassScriptPhysician profile
Jawad A Ilyas
NPI 1629276159
$40,116.84
in general payments reported to CMS, 2019-2025
41 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,614 · 2020: $399 · 2021: $3,884 · 2022: $8,399 · 2023: $3,221 · 2024: $1,352 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $4,570 · Education: $35.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,216.00 |
| Food and Beverage | $4,570.32 |
| Education | $35.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23,470.71 | 2019-2025 | |
| Madrigal Pharmaceuticals | $11,508.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $537.79 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $506.85 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Gilead Sciences, INC. | $335.57 | 2019-2025 | |
| Pfizer INC. | $302.14 | 2019-2025 | |
| Genzyme Corporation | $288.85 | 2022-2025 | |
| Janssen Biotech, INC. | $277.72 | 2019-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $268.46 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $216.38 | 2024-2025 | Omvoh, Zepbound |
| Boston Scientific Corporation | $215.17 | 2020-2025 | Axonics, Watchman Flx |
| Celgene Corporation | $203.10 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $203.08 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $197.92 | 2019-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $192.88 | 2024-2025 | Iqirvo, Bylvay |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $184.03 | 2021-2025 | Pancreaze, Qsymia |
| Qol Medical, LLC | $178.33 | 2023-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $127.91 | 2021-2023 | Injectafer |
| Astellas Pharma US INC | $100.23 | 2022-2023 | Cresemba |
| Mallinckrodt Hospital Products INC. | $78.08 | 2025 | Terlivaz |
| Aimmune Therapeutics, INC. | $71.58 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $70.39 | 2024-2025 | Vegzelma, Zymfentra |
| Novo Nordisk INC | $52.58 | 2024-2025 | Wegovy |
| Braintree Laboratories, INC. | $51.03 | 2022-2024 | Sutab, Suflave |
| Ardelyx, INC. | $48.21 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $44.57 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.02 | 2023 | |
| Baxter Healthcare | $41.79 | 2020 | |
| Organon LLC | $40.40 | 2024 | |
| Shionogi INC | $33.07 | 2019 | |
| Orphalan INC | $28.92 | 2025 | Cuvrior |
| Evoke Pharma, INC. | $28.58 | 2022 | |
| Amgen INC. | $25.18 | 2023 | Amjevita, Avsola |
| Phathom Pharmaceuticals, INC. | $22.25 | 2024 | Voquezna |
| Ferring Pharmaceuticals INC. | $21.73 | 2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $18.66 | 2024 | |
| Intra-Sana Laboratories | $17.84 | 2022 | |
| Exact Sciences Corporation | $17.40 | 2023 | Cologuard Collection Kit |
| Ucb, INC. | $16.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.61 | 2021 | |
| Redhill Biopharma INC. | $14.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawad Ilyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.